FindTrial
Sign In

Clinical study of tizanidine combined with intrathecal analgesic pump on cancer pain

Clinical study of tizanidine combined with intrathecal analgesic pump on cancer pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040107
Enrollment
Unknown
Registered
2020-11-21
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

1:intrathecal analgesic pump
2:tizanidine + intrathecal analgesic pump

Sponsors

Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. the diagnosis of cancer pain, oral opioid dose is large or intolerable; 2. Aged 30 to 70 years; 3. VAS score >=4; 4. provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Communication disorder; 2. Severe heart, lung, liver and kidney dysfunction; 3. Definitely diagnosed neuropsychiatric diseases, such as dementia, Parkinson's syndrome, myasthenia gravis, schizophrenia, epilepsy, etc.; 4. Severe infection; 5. Alcohol Or history of drug abuse; 6. Major depression.

Design outcomes

Primary

MeasureTime frame
VAS;—

Secondary

MeasureTime frame
dose of morphine;—

Countries

China

Contacts

Public ContactMeng Chao
mengchao1119@hotmail.com+86 18661808786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026